In conclusion, we show that combination immunotherapy using OX40 agonism, TIM3 inhibition and Poly(I:C) injected intratumorally into A20 lymphoma tumors leads to complete tumor regression and improved long-term survival. The gene discussed is TNFRSF4; the disease is lymphoma.